このエントリーをはてなブックマークに追加
ID 13223
Eprint ID
13223
FullText URL
Thumnail 119_285.pdf 387 KB
Title Alternative
II Standard treatment for advanced lung cancer
Author
Takigawa, Nagio
Oze, Isao
Yasugi, Masayuki
Ochi, Nobuaki
Harada, Daijiro
Keywords
放射線化学療法
分子標的治療
血管新生阻害薬
受容体チロシンキナーゼ阻害薬
Note
特集 がんの標準的治療
Published Date
2008-01-04
Publication Title
岡山医学会雑誌
Publication Title Alternative
Journal of Okayama Medical Association
Volume
volume119
Issue
issue3
Publisher
岡山医学会
Publisher Alternative
Okayama Medical Association
Start Page
285
End Page
292
ISSN
00301558
NCID
AN00032489
Content Type
Journal Article
Related Url
http://www.okayama-u.ac.jp/user/oma/
References
1) Takigawa N, Kiura K, Segawa Y, Watanabe Y, Kamei H, Moritaka T, Shibayama T, Ueoka H, Gemba K, Yonei T, Tabata M, Shinkai T, Hiraki S, Takemoto M, Kanazawa S, Matsuo K, Tanimoto M ; Okayama Lung Cancer Study Group : Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer. Br J Cancer (2006) 95, 1142-1144.
2) Kiura K, Takigawa N, Segawa Y, Tabata M, Shibayama T, Gemba K, Bessho A, Fujimoto N, Takata I, Hotta K, Fujiwara K, Tokuda Y, Kuyama S, Shinkai T, Ueoka H, Tanimoto M ; Okayama Lung Cancer Study Group : Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer : a phase I/II trial. J Thorac Oncol (2007) 2, 44-50.
3) Hotta K, Kiura K, Toyooka S, Takigawa N, Soh J, Fujiwara Y, Tabata M, Date H, Tanimoto M : Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer. J Thorac Oncol (2007) 2, 632-637.
4) Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L ; International Association for the Study of Lung Cancer International Staging Committee ; Participating Institutions : The IASLC Lung Cancer Staging Project : proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol (2007) 2, 706-714.
5) Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y : Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol (1999) 17, 2692-2699.
6) Kiura K, Ueoka H, Segawa Y, Tabata M, Kamei H, Takigawa N, Hiraki S, Watanabe Y, Bessho A, Eguchi K, Okimoto N, Harita S, Takemoto M, Hiraki Y, Harada M, Tanimoto M ; Okayama Lung Cancer Study Group : Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer (2003) 89, 795-802.
7) Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN Jr, Burris H, Gumerlock P, Kuebler JP, Bearden JD 3rd, Crowley J, Livingston R ; Southwest Oncology Group : Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer : phase II Southwest Oncology Group Study S9504. J Clin Oncol (2003) 21, 2004-2010.
8) 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), (2007) abstract #7512.
9) 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), (2007) abstract #7513.
10) Katayama H, Ueoka H, Kiura K, Tabata M, Kozuki T, Tanimoto M, Fujiwara T, Tanaka N, Date H, Aoe M, Shimizu N, Takemoto M, Hiraki Y : Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer. Br J Cancer (2004) 90, 979-984.
11) 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), (2005) abstract #7014.
12) Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M : EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy. Science (2004) 304, 1497-1500.
13) Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 350, 2129-2139.
14) Cohen S, Carpenter G, King L Jr : Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem (1980) 255, 4834-4842.
15) Ward WH, Cook PN, Slater AM, Davies DH, Holdgate GA, and Green LR : Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem Pharmacol (1994) 48, 659-666.
16) Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF : Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 97, 339-346.
17) Okamoto I, Araki J, Suto R, Shimada M, Nakagawa K, Fukuoka M : EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann Oncol (2006) 17, 1028-1029.
18) Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE : Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev (2006) 20, 1496-1510.
19) Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Janne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK : The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell (2006) 9, 485-495.
20) Ohashi K, Rai K, Kiura K, Osawa M, Hirano S, Fujiwara Y, Yoshino T, Takigawa N, Takata M, Tanimoto M : Transgenic mice with mouse EGFR mutation developed lung adenocarcinoma. 2007 AACR Annual Meeting (2007) Abstract #LB-106.
21) Gazdar AF, Shigematsu H, Herz J, Minna JD : Mutations and addiction to EGFR : The Achilles ‘heal’ of lung cancers? Trends Mol Med (2004) 10, 481-486.
22) Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ : Structures of lung cancer-derived EGFR mutants and inhibitor complexes : mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell (2007) 11, 217-227.
23) Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B : EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 352, 786-792.
24) Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H : Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 2, e 73.
25) Toyooka S, Kiura K, Mitsudomi T : EGFR mutation and response of lung cancer to gefitinib. N Engl J Med (2005) 352, 2136.
26) Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA : MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 316, 1039-1043.
27) Thatcher N, Chang A, Parikh P, Rodrigues PJ, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K : Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer : results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet (2005) 366, 1527-1537.
28) 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), (2007) Abstract #LBA7509.
29) Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L ; NationalCancer Institute of Canada Clinical Trials Group : Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 353, 123-132.
30) Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N : Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 362, 841-844.
31) Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA : A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 349, 427-434.
32) Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F : Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 350, 2335-2342.
33) Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS : Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol (2005) 23, 792-799.
34) Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F : Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2004) 22, 2184-2191.
35) Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH : Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 355, 2542-2550.
36) 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement) (2007) Abstract #LBA7514.
37) Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A, Rossi A : Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist (2007) 12, 191-200.
38) Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM ; TARGET Study Group : Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 356, 125-134.
39) 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), (2007) Abstract #LBA1.
40) 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), (2006) Abstract #7002.
41) Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA : Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 356, 115-124.
42) Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG : Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib : a randomised controlled trial. Lancet (2006) 368, 1329-1338.
43) 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement) (2006) Abstract #7001.
44) Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Ple PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO : Novel 4-anilinoquinazolines with C-7 basic side chains : design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem (2002) 45, 1300-1312.
45) Herbst RS, O'neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A : Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. J Clin Oncol (2007) Oct 1 ; [Epub ahead of print].
46) 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006 : 7067.
47) Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H, Okamoto H, Ogura T, Yokoyama A, Seki N, Asaka-Amano Y, Harada M, Tagawa A, Kunikane H, Yokoba M, Uematsu K, Kuriyama T, Kuroiwa Y, Watanabe K ; Thoracic Oncology Research Group Study 0301 : Phase II trial of amrubicin for treatment of refractory or relapsed small-celllung cancer : Thoracic Oncology Research Group Study 0301. J Clin Oncol (2006) 24, 5448-5453.
48) Ohonoshi T, Ueoka H, Kawahara S, Kiura K, Kamei H, Hiraki Y, Segawa Y, Hiraki S, Kimura I : Comparative study of prophylactic cranial irradiation in patients with small cell lung cancer achieving a complete response : a long-term follow-up result. Lung Cancer (1993) 10, 47-54.
49) Auperin A, Arriagada R, Pignon JP, Le PAchoux C, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, Ueoka H, Wagner H, Aisner J : Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med (1999) 341, 476-484.
50) Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, Postmus P, Collette L, Musat E, Senan S ; EORTC Radiation Oncology Group and Lung Cancer Group : Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med (2007) 357, 664-672.
language
日本語
Copyright Holders
岡山医学会
File Version
publisher
Refereed
True
DOI
Eprints Journal Name
joma